Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans

We have evaluated an oral vaccine based on an Salmonella enteric serovar typhi (S. typhi) Ty2 derivative TSB7 harboring deletion mutations in ssaV (SPI-2) and aroC together with a chromosomally integrated copy of eltB encoding the B subunit of enterotoxigenic Escherichia coli heat labile toxin (LT-B...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 25; no. 21; pp. 4175 - 4182
Main Authors Khan, S., Chatfield, S., Stratford, R., Bedwell, J., Bentley, M., Sulsh, S., Giemza, R., Smith, S., Bongard, E., Cosgrove, C.A., Johnson, J., Dougan, G., Griffin, G.E., Makin, J., Lewis, D.J.M.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 22.05.2007
Elsevier
Elsevier Science
Subjects
Online AccessGet full text
ISSN0264-410X
1873-2518
DOI10.1016/j.vaccine.2007.03.007

Cover

More Information
Summary:We have evaluated an oral vaccine based on an Salmonella enteric serovar typhi (S. typhi) Ty2 derivative TSB7 harboring deletion mutations in ssaV (SPI-2) and aroC together with a chromosomally integrated copy of eltB encoding the B subunit of enterotoxigenic Escherichia coli heat labile toxin (LT-B) in volunteers. Two oral doses of 108 or 109CFU were administered to two groups of volunteers and both doses were well tolerated, with no vaccinemia, and only transient stool shedding. Immune responses to LT-B and S. typhi lipopolysaccharide were demonstrated in 67 and 97% of subjects, respectively, without evidence of anti-carrier immunity preventing boosting of LT-B responses in many cases. Further development of this salmonella-based (spi-VEC) system for oral delivery of heterologous antigens appears warranted.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2007.03.007